摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-(6-cyclopropyl-5,7-dioxo-2,3,4,5,6,7-hexahydro-1H-pyrrolo[3,4-b]pyridin-1-yl)-N-(6-(6-methylpyridin-3-yl)pyridazin-3-yl)acetamide

中文名称
——
中文别名
——
英文名称
2-(6-cyclopropyl-5,7-dioxo-2,3,4,5,6,7-hexahydro-1H-pyrrolo[3,4-b]pyridin-1-yl)-N-(6-(6-methylpyridin-3-yl)pyridazin-3-yl)acetamide
英文别名
2-(6-cyclopropyl-5,7-dioxooctahydro-1H-pyrrolo[3,4-b]pyridin-1-yl)-N-(6-(6-methylpyridin-3-yl)pyridazin-3-yl)acetamide;2-(6-cyclopropyl-5,7-dioxo-3,4-dihydro-2H-pyrrolo[3,4-b]pyridin-1-yl)-N-[6-(6-methylpyridin-3-yl)pyridazin-3-yl]acetamide
2-(6-cyclopropyl-5,7-dioxo-2,3,4,5,6,7-hexahydro-1H-pyrrolo[3,4-b]pyridin-1-yl)-N-(6-(6-methylpyridin-3-yl)pyridazin-3-yl)acetamide化学式
CAS
——
化学式
C22H22N6O3
mdl
——
分子量
418.455
InChiKey
AWFKDFGAFDJYLS-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.9
  • 重原子数:
    31
  • 可旋转键数:
    5
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.36
  • 拓扑面积:
    108
  • 氢给体数:
    1
  • 氢受体数:
    7

反应信息

  • 作为产物:
    描述:
    2,3-吡啶二羧酸酐 在 lithium hydroxide monohydrate 、 palladium 10% on activated carbon 、 氢气potassium carbonate三乙胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下, 以 四氢呋喃甲醇二氯甲烷甲苯乙腈 为溶剂, 反应 66.0h, 生成 2-(6-cyclopropyl-5,7-dioxo-2,3,4,5,6,7-hexahydro-1H-pyrrolo[3,4-b]pyridin-1-yl)-N-(6-(6-methylpyridin-3-yl)pyridazin-3-yl)acetamide
    参考文献:
    名称:
    Scaffold Hopping and Optimization of Maleimide Based Porcupine Inhibitors
    摘要:
    Porcupine is an O-acyltransferase that regulates Wnt secretion. Inhibiting porcupine may block the Wnt pathway which is often dysregulated in various cancers. Consequently porcupine inhibitors are thought to be promising oncology therapeutics. A high throughput screen against porcupine revealed several potent hits that were confirmed to be Wnt pathway inhibitors in secondary assays. We developed a pharmacophore model and used the putative bioactive conformation of a xanthine inhibitor for scaffold hopping. The resulting maleimide scaffold was optimized to subnanomolar potency while retaining good physical druglike properties. A preclinical development candidate was selected for which extensive in vitro and in vivo profiling is reported.
    DOI:
    10.1021/acs.jmedchem.7b00662
点击查看最新优质反应信息

文献信息

  • [EN] MALEIMIDE DERIVATIVES AS MODULATORS OF WNT PATHWAY<br/>[FR] DÉRIVÉS DE MALÉIMIDE COMME MODULATEURS D'UNE VOIE WNT
    申请人:AGENCY SCIENCE TECH & RES
    公开号:WO2015094118A1
    公开(公告)日:2015-06-25
    The present invention relates to compounds of formula (I), combinations and uses thereof for disease therapy, or a pharmaceutically acceptable salt, solvate or polymorph therof, including all tautomers and stereoisomers thereof wherein R1represents optionally substituted alkyl (wherein optional substituents include one or more substituents each independently selected from C1-6alkoxy); optionally substituted carbocyclyl (wherein optional substituents include one or more substituents each independently selected from C1-6alkyl, C1-6alkoxy, C1-6haloalkyl, C1-6haloalkoxy and halo); or -alkylaryl; R2 represents H; or alkyl; R3 represents H; or alkyl; U, V and W represent -(CH2)-; or U and V together represent -CH=CH- and W represents C=O; Y represents aryl; heteroaryl; optionally substituted carbocyclyl (wherein optional substituents include one or more substituents each independently selected from C1-6alkyl, C1-6alkoxy, C1-6haloalkyl, C1-6haloalkoxy and halo); or optionally substituted heterocyclyl (wherein optional substituents include one or more substituents each independently selected from C1-6alkyl, C1-6 alkoxy, -C(O)OC1-6alkyl, -C(O)C1-6alkyl and-C(O)NHC1-6alkyl); and Z represents aryl; heteroaryl; optionally substituted carbocyclyl (wherein optional substituents include one or more substituents each independently selected from C1-6alkyl, C1-6alkoxy, C1- 6haloalkyl, C1-6haloalkoxy and halo); or optionally substituted heterocyclyl (wherein optional substituents include one or more substituents each independently selected from C1-6alkyl, C1-6. alkoxy, -C(O)OC1-6alkyl, -C(O)C1-6alkyl and -C(O)NHC1-6alkyl).
    本发明涉及式(I)的化合物,其组合物和用于疾病治疗的用途,或其药学上可接受的盐,溶剂或多晶体,包括其所有互变异构体和立体异构体,其中R1代表可选取代的烷基(其中可选取代基包括一个或多个从C1-6烷氧基中独立选择的基团);可选取代的碳环烷基(其中可选取代基包括一个或多个从C1-6烷基,C1-6烷氧基,C1-6卤代烷基,C1-6卤代烷氧基和卤素中独立选择的基团);或-烷基芳基;R2代表H;或烷基;R3代表H;或烷基;U,V和W代表-(CH2)-;或U和V组成-CH=CH-,而W代表C=O;Y代表芳基;杂芳基;可选取代的碳环烷基(其中可选取代基包括一个或多个从C1-6烷基,C1-6烷氧基,C1-6卤代烷基,C1-6卤代烷氧基和卤素中独立选择的基团);或可选取代的杂环烷基(其中可选取代基包括一个或多个从C1-6烷基,C1-6烷氧基,-C(O)OC1-6烷基,-C(O)C1-6烷基和-C(O)NHC1-6烷基中独立选择的基团);而Z代表芳基;杂芳基;可选取代的碳环烷基(其中可选取代基包括一个或多个从C1-6烷基,C1-6烷氧基,C1-6卤代烷基,C1-6卤代烷氧基和卤素中独立选择的基团);或可选取代的杂环烷基(其中可选取代基包括一个或多个从C1-6烷基,C1-6烷氧基,-C(O)OC1-6烷基,-C(O)C1-6烷基和-C(O)NHC1-6烷基中独立选择的基团)。
  • MALEIMIDE DERIVATIVES AS MODULATORS OF WNT PATHWAY
    申请人:Agency for Science, Technology and Research
    公开号:EP3083622B1
    公开(公告)日:2018-03-21
  • US9981964B2
    申请人:——
    公开号:US9981964B2
    公开(公告)日:2018-05-29
  • Scaffold Hopping and Optimization of Maleimide Based Porcupine Inhibitors
    作者:Soo Yei Ho、Jenefer Alam、Duraiswamy Athisayamani Jeyaraj、Weiling Wang、Grace Ruiting Lin、Shi Hua Ang、Eldwin Sum Wai Tan、May Ann Lee、Zhiyuan Ke、Babita Madan、David M. Virshup、Li Jun Ding、Vithya Manoharan、Yun Shan Chew、Choon Bing Low、Vishal Pendharkar、Kanda Sangthongpitag、Jeffrey Hill、Thomas H. Keller、Anders Poulsen
    DOI:10.1021/acs.jmedchem.7b00662
    日期:2017.8.10
    Porcupine is an O-acyltransferase that regulates Wnt secretion. Inhibiting porcupine may block the Wnt pathway which is often dysregulated in various cancers. Consequently porcupine inhibitors are thought to be promising oncology therapeutics. A high throughput screen against porcupine revealed several potent hits that were confirmed to be Wnt pathway inhibitors in secondary assays. We developed a pharmacophore model and used the putative bioactive conformation of a xanthine inhibitor for scaffold hopping. The resulting maleimide scaffold was optimized to subnanomolar potency while retaining good physical druglike properties. A preclinical development candidate was selected for which extensive in vitro and in vivo profiling is reported.
查看更多